ALK and non-small cell lung carcinoma: Our findings imply that appropriate decision-making in terms of anti-cancer drug selection (EGFR tyrosine kinase inhibitors, ALK inhibitors, or intravenous cytotoxic chemotherapy) is possible based on molecular data obtained from EBUS-GS specimens of patients with advanced NSCLC.